Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE7.3800
- TODAY'S CHANGE (%)-0.2600 (-3.4031%)
- Bid / Lots7.3800/ 1
- Ask / Lots7.4100/ 4
- Open / Previous Close7.5900 / 7.6400
- Day Range
- 52 Week Range
- Volume214,686
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 5159 | 7.65 |
| 09:36 ET | 600 | 7.56 |
| 09:38 ET | 200 | 7.49 |
| 09:39 ET | 2153 | 7.53 |
| 09:41 ET | 100 | 7.6 |
| 09:43 ET | 1300 | 7.6 |
| 09:45 ET | 200 | 7.63 |
| 09:50 ET | 100 | 7.58 |
| 09:56 ET | 100 | 7.58 |
| 09:57 ET | 5044 | 7.72 |
| 09:59 ET | 100 | 7.73 |
| 10:01 ET | 400 | 7.75 |
| 10:03 ET | 2606 | 7.75 |
| 10:06 ET | 58336 | 7.81 |
| 10:08 ET | 2232 | 7.805 |
| 10:10 ET | 1400 | 7.83 |
| 10:12 ET | 100 | 7.835 |
| 10:14 ET | 1212 | 7.79 |
| 10:15 ET | 561 | 7.795 |
| 10:17 ET | 3712 | 7.71 |
| 10:21 ET | 100 | 7.72 |
| 10:24 ET | 779 | 7.79 |
| 10:26 ET | 300 | 7.74 |
| 10:28 ET | 101 | 7.7637 |
| 10:30 ET | 3360 | 7.78 |
| 10:32 ET | 2592 | 7.83 |
| 10:35 ET | 400 | 7.825 |
| 10:37 ET | 800 | 7.79 |
| 10:39 ET | 1002 | 7.76 |
| 10:44 ET | 968 | 7.7375 |
| 10:46 ET | 417 | 7.72 |
| 10:48 ET | 2127 | 7.75 |
| 10:51 ET | 600 | 7.755 |
| 10:53 ET | 840 | 7.74 |
| 10:55 ET | 400 | 7.72 |
| 10:57 ET | 100 | 7.725 |
| 11:02 ET | 1100 | 7.74 |
| 11:04 ET | 200 | 7.74 |
| 11:06 ET | 1207 | 7.7 |
| 11:08 ET | 300 | 7.71 |
| 11:09 ET | 400 | 7.68 |
| 11:11 ET | 104 | 7.67 |
| 11:15 ET | 500 | 7.64 |
| 11:18 ET | 5148 | 7.56 |
| 11:20 ET | 200 | 7.54 |
| 11:22 ET | 100 | 7.54 |
| 11:24 ET | 1443 | 7.44 |
| 11:27 ET | 100 | 7.41 |
| 11:31 ET | 1551 | 7.4518 |
| 11:36 ET | 100 | 7.47 |
| 11:38 ET | 4102 | 7.5 |
| 11:42 ET | 3034 | 7.455 |
| 11:45 ET | 100 | 7.49 |
| 11:47 ET | 200 | 7.49 |
| 11:49 ET | 100 | 7.49 |
| 11:54 ET | 4325 | 7.57 |
| 11:58 ET | 400 | 7.55 |
| 12:00 ET | 100 | 7.54 |
| 12:02 ET | 1957 | 7.48 |
| 12:03 ET | 400 | 7.47 |
| 12:05 ET | 400 | 7.45 |
| 12:07 ET | 1776 | 7.485 |
| 12:09 ET | 700 | 7.49 |
| 12:14 ET | 1100 | 7.465 |
| 12:16 ET | 100 | 7.45 |
| 12:18 ET | 300 | 7.45 |
| 12:21 ET | 3212 | 7.485 |
| 12:23 ET | 6367 | 7.54 |
| 12:25 ET | 200 | 7.56 |
| 12:27 ET | 677 | 7.56 |
| 12:30 ET | 500 | 7.53 |
| 12:32 ET | 400 | 7.54 |
| 12:34 ET | 2339 | 7.58 |
| 12:36 ET | 1470 | 7.52 |
| 12:39 ET | 211 | 7.54 |
| 12:41 ET | 814 | 7.51 |
| 12:43 ET | 700 | 7.52 |
| 12:45 ET | 2241 | 7.54 |
| 12:48 ET | 700 | 7.53 |
| 12:50 ET | 700 | 7.52 |
| 12:52 ET | 800 | 7.515 |
| 12:54 ET | 500 | 7.505 |
| 12:56 ET | 1068 | 7.485 |
| 12:57 ET | 1800 | 7.43 |
| 12:59 ET | 100 | 7.42 |
| 01:01 ET | 300 | 7.405 |
| 01:03 ET | 200 | 7.38 |
| 01:06 ET | 100 | 7.38 |
| 01:08 ET | 200 | 7.41 |
| 01:10 ET | 300 | 7.39 |
| 01:12 ET | 300 | 7.405 |
| 01:14 ET | 300 | 7.39 |
| 01:15 ET | 1100 | 7.41 |
| 01:19 ET | 800 | 7.38 |
Jun 7, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Jun 07, 2024 by Dow Jones
4:30PM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 515.1M | -4.1x | --- |
Lexeo Therapeutics Inc | 514.3M | -5.4x | --- |
Mind Medicine (MindMed) Inc | 508.1M | -2.4x | --- |
Astria Therapeutics Inc | 507.9M | -3.9x | --- |
Altimmune Inc | 510.5M | -4.3x | --- |
Annexon Inc | 522.6M | -3.2x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $515.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
